FDA accepts CAM2029 NDA resubmission for Acromegaly, sets December 2026 PDUFA Date – Camurus
Camurus announced that the FDA has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with… read more.




